Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04895150
Other study ID # Gazi University 408
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date May 15, 2022

Study information

Verified date May 2022
Source Gazi University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main aim of the study is to evaluate upper extremity exercise capacity and muscle oxygenation in patients with primary ciliary dyskinesia. The secondary aim of the study is to evaluate respiratory function, respiratory muscle strength and endurance, peripheral muscle strength, balance, physical activity level and quality of life in patients with primary ciliary dyskinesia and compare all parameters with healthy controls.


Description:

Primary ciliary dyskinesia (PCD) is a genetic, heterogeneous disease caused by cilia absence or dysfunction. Impaired function of motile cilia leads to impaired mucociliary clearance, recurrent chest infections, and progressive destruction of the lung structure. Clinical features include neonatal respiratory distress syndrome, chronic daily productive cough, chronic nasal congestion, and chronic or recurrent otitis media. Pulmonary functions, exercise capacity, respiratory muscle strength and endurance, peripheral muscle strength, physical activity level and quality of life were affected in patients. The number of studies on these subjects is limited. Pulmonary function and extremity muscle strength are determinants of exercise capacity in chronic obstructive pulmonary disease. Decreased strength and endurance in the limb muscles is associated with exercise intolerance. Patients have decreased upper extremity muscle strength. There is no study in the literature evaluating upper extremity exercise capacity in patients with PCD. Measuring the oxygen saturation of cardiorespiratory and peripheral muscles is important for understanding the dynamics of oxygen delivery and consumption during exercise. There are no studies in the literature evaluating muscle oxygenation in this patient population. The main aim of the study is to evaluate upper extremity exercise capacity and muscle oxygenation in patients with primary ciliary dyskinesia. The secondary aim of the study is to evaluate respiratory function, respiratory muscle strength and endurance, peripheral muscle strength, balance, physical activity level and quality of life in patients with primary ciliary dyskinesia and compare them with healthy controls. The study was planned cross-sectional. Patients with primary ciliary dyskinesia referred to the Cardiopulmonary Rehabilitation Unit of Gazi University Physiotherapy and Rehabilitation Department by the physicians of the Department of Pediatric Pulmonary Diseases of Gazi University Faculty of Medicine will be included in the study. At least 18 patients with primary ciliary dyskinesia and at least 18 healthy controls of similar age and sex will be evaluated in the study. The assessments will be completed in two days. Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation ("Moxy" monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance("Biodex Balance System®" and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3) will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date May 15, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: Patients; - 6-18 years old - Diagnosed with primary ciliary dyskinesia - Stability of clinical condition Healthy controls; - 6-18 years old Exclusion Criteria: Patients; - Diagnosed neurological, cognitive problem that can affect evaluations, - Acute pneumonia or any infection - History of exacerbation in the last 1 month - More than 10% change in FEV1 in the last 6 months - History of coronavirus disease (COVID-19) - History of smoking - Diagnosed vision, hearing, vestibular, or neurological problems that can affect balance - Diagnosed orthopedic problems affecting mobility or a history of musculoskeletal surgery Healthy controls; - Diagnosed neurological, cognitive problem that can affect evaluations - Diagnosed vision, hearing, vestibular, or neurological problems that can affect balance - History of coronavirus disease (COVID-19) - History of smoking - Trouble understanding and following the exercise test instruction

Study Design


Locations

Country Name City State
Turkey Gazi University Ankara
Turkey Gazi University, Faculty of Health Science Ankara

Sponsors (1)

Lead Sponsor Collaborator
Gazi University

Country where clinical trial is conducted

Turkey, 

References & Publications (5)

Behan L, Rubbo B, Lucas JS, Dunn Galvin A. The patient's experience of primary ciliary dyskinesia: a systematic review. Qual Life Res. 2017 Sep;26(9):2265-2285. doi: 10.1007/s11136-017-1564-y. Epub 2017 Mar 30. Review. — View Citation

Denizoglu Kulli H, Gurses HN, Zeren M, Ucgun H, Cakir E. Do pulmonary and extrapulmonary features differ among cystic fibrosis, primary ciliary dyskinesia, and healthy children? Pediatr Pulmonol. 2020 Nov;55(11):3067-3073. doi: 10.1002/ppul.25052. Epub 2020 Sep 11. — View Citation

Madsen A, Green K, Buchvald F, Hanel B, Nielsen KG. Aerobic fitness in children and young adults with primary ciliary dyskinesia. PLoS One. 2013 Aug 19;8(8):e71409. doi: 10.1371/journal.pone.0071409. eCollection 2013. — View Citation

Ring AM, Buchvald FF, Holgersen MG, Green K, Nielsen KG. Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis. Respir Med. 2018 Jun;139:79-85. doi: 10.1016/j.rmed.2018.05.001. Epub 2018 May 3. — View Citation

Valerio G, Giallauria F, Montella S, Vaino N, Vigorito C, Mirra V, Santamaria F. Cardiopulmonary assessment in primary ciliary dyskinesia. Eur J Clin Invest. 2012 Jun;42(6):617-22. doi: 10.1111/j.1365-2362.2011.02626.x. Epub 2011 Nov 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Upper extremity exercise capacity Upper extremity exercise capacity will be evaluated with the six-minute pegboard and ring test (6-PBRT). A pegboard with two upper and lower bars set at participants shoulder level and above the shoulder level will used. Ten rings will placed on both the lower bars. Patients will be asked to move a single ring at a time with both hands from the lower bars to the upper. The score is the total number of rings moved the six-minute period. First Day
Primary Muscle Oxygenation Muscle oxygenation assessment will be performed using the Moxy monitor (Moxy, Fortiori Design LLC, Minnesota, USA). The device will be placed on the 1/3 lower motor point of the quadriceps muscle group of the dominant leg and on the dominant arm deltoid muscle. A minimum of 3 minutes will be waited until the resting measurements and skeletal muscle oxygenation (StO2) signal stabilize. The measurements will be repeated during six minute walking test and six minute pegboard and ring test. First Day
Secondary Functional exercise capacity Functional exercise capacity will be evaluated with 6-minute walking test according to the American Thoracic Society and European Respiratory Society criteria. First Day
Secondary Balance Static balance assessment will be evaluated using the "Biodex Balance System®". The test period will be 20 seconds, and there will be a 10-second break between evaluations. General stability index, anterior / posterior (AP) stability index, medial / lateral (ML) stability index and their standard deviations will be obtained from the system as a result of the test. The tests will first be carried out on the hard ground with open eyes. The tests will second be carried out on the hard ground with closed eyes. The tests will third be carried out on the soft ground with open eyes. Dynamic balance will be evaluated with the Y balance test. Second day
Secondary Physical activity (Total energy expenditure) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second day
Secondary Physical activity (Active energy expenditure (joule / day) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second day
Secondary Physical activity (Physical activity time (min / day) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second Day
Secondary Physical activity (Average metabolic equivalent (MET / day) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second Day
Secondary Physical activity (Number of steps (steps / day) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second Day
Secondary Physical activity (Time spent lying down (min / day) days) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second Day
Secondary Physical activity (Sleep time (min / day) Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD). The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days. The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program. Second Day
Secondary Respiratory muscle strength Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength will be measured with a portable mouth pressure measuring device according to American Thoracic Society and European Respiratory Society criteria. First day
Secondary Respiratory muscle endurance Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load. The test will be started with 20% of the maximal inspiratory pressure and the pressure will be increased to 40%, 60%, 80% and 100% every two minutes. Patients will be asked to continue breathing through the device during the test. If the individual cannot breathe 3 consecutive times, the test will be terminated by the physiotherapist. During the test, the number of breaths delivered and the maximal time reached during each 2-minute period will be recorded.The total duration of the test and the maximum pressure value at which it continues to breathe for at least 1 minute will be multiplied. The value found will be recorded as the respiratory muscle endurance value. Second Day
Secondary Pulmonary function (Forced vital capacity (FVC)) Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced vital capacity (FVC) will be measured. First Day
Secondary Pulmonary function (Forced expiratory volume in the first second (FEV1)) Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced expiratory volume in the first second (FEV1) will be measured. First Day
Secondary Pulmonary function (FEV1 / FVC) Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. FEV1 / FVC will be measured. First Day
Secondary Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)) Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be measured. First Day
Secondary Pulmonary function (Peak flow rate (PEF)) Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Peak flow rate (PEF) will be measured. First Day
Secondary Life quality Quality of life will be evaluated with the Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)(Turkish version). The scale have well-established reliability and validity. There are four separate versions of QOL-PCD for three separate age-appropriate.The scale includes questions about physical function, emotional function, social function, respiratory symptoms, treatment burden, hearing symptoms, role, health perceptions, vitality, eating and weight. The scale included sub-groups involving different situations according to the different ages. The total numbers of items in the scale are 37 in the questionnaire for children, 43 in the one for adolescents, 49 in the one for adults, 41 in the parents of the patients in the age group of 6-12 years. Items are rated according to a 4-point scale. Higher scores indicate better quality of life. Second day
See also
  Status Clinical Trial Phase
Recruiting NCT05889013 - Utility of PCD Diagnostics to Improve Clinical Care
Recruiting NCT01246258 - Otolith Function in Patients With Primary Ciliary Dyskinesia N/A
Completed NCT04858191 - Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia
Completed NCT05712798 - Physiological Responses to Exercise Tests in Primary Ciliary Dyskinesia Compared With Healthy Individuals
Completed NCT03370029 - Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Recruiting NCT05374720 - Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy N/A
Completed NCT05816876 - Muscle Function, Exercise Capacity and Physical Activity Level in Primary Ciliary Dyskinesia and Kartagener Syndrome
Recruiting NCT04717115 - Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)
Recruiting NCT03320382 - Multiple Breath Washout, a Clinimetric Dataset
Recruiting NCT03279965 - MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia N/A
Recruiting NCT04602481 - COVID-19 in People With Primary Ciliary Dyskinesia
Not yet recruiting NCT02704455 - Registry Study on Primary Ciliary Dyskinesia in Chinese Children N/A
Completed NCT00323167 - Rare Genetic Disorders of the Breathing Airways
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Completed NCT03832491 - Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia N/A
Recruiting NCT05951478 - DCP (RaDiCo Cohort) (RaDiCo-DCP)
Completed NCT06028607 - Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia N/A
Recruiting NCT05685186 - A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
Recruiting NCT05161858 - Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia